ReviewBMB reports2015
Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyond.
Review in BMB reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Unraveling Molecular Targets for Neurodegenerative Diseases ThroughInternational journal of molecular sciences · 2025Review
- Virtual screening: hope, hype, and the fine line in between.Expert opinion on drug discovery · 2025Review
- Animal model for high consumption and preference of ethanol and its interplay with high sugar and butter diet, behavior, and neuroimmune system.Frontiers in nutrition · 2023Article
- Mitochondrial ROS promotes susceptibility to infection via gasdermin D-mediated necroptosis.Cell · 2022Article
- Niacin and Butyrate: Nutraceuticals Targeting Dysbiosis and Intestinal Permeability in Parkinson's Disease.Nutrients · 2020Review
- Innate and adaptive immune responses in Parkinson's disease.Progress in brain research · 2020Review
- Patients with Inflammatory Bowel Disease Are at an Increased Risk of Parkinson's Disease: A South Korean Nationwide Population-Based Study.Journal of clinical medicine · 2019Article
- Shared Molecular Signatures Across Neurodegenerative Diseases and Herpes Virus Infections Highlights Potential Mechanisms for Maladaptive Innate Immune Responses.Scientific reports · 2019Article
- Altered Gut Microbiome and Intestinal Pathology in Parkinson's Disease.Journal of movement disorders · 2019Article
- Nonpharmacological Modulation of Chronic Inflammation in Parkinson's Disease: Role of Diet Interventions.Parkinson's disease · 2019Review
- On cell death in the intestinal epithelium and its impact on gut homeostasis.Current opinion in gastroenterology · 2018Review
- Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease.JAMA neurology · 2018Article
- Identification of Natural Compounds against Neurodegenerative Diseases Using In Silico Techniques.Molecules (Basel, Switzerland) · 2018Article
- Beneficial effects ofJournal of ginseng research · 2018Review
- Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.Cell death & disease · 2018Article
- The Receptor Interacting Protein Kinases in the Liver.Seminars in liver disease · 2018Review
- LRRK2 Contributes to Secondary Brain Injury Through a p38/Drosha Signaling Pathway After Traumatic Brain Injury in Rats.Frontiers in cellular neuroscience · 2018Article
- In vitro assessment of selected Korean plants for antioxidant and antiacetylcholinesterase activities.Pharmaceutical biology · 2017Article
- Integrated analysis of differential expression and alternative splicing of non-small cell lung cancer based on RNA sequencing.Oncology letters · 2017Article
- The gut-brain axis: is intestinal inflammation a silent driver of Parkinson's disease pathogenesis?NPJ Parkinson's disease · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson's disease (PD). As such, functions and dysfunctions of LRRK2 in PD have been the subject of extensive investigation. In addition to PD, increasing evidence is suggesting that LRRK2 is associated with a wide range of diseases. Genome-wide association studies have implicated LRRK2 in Crohn's disease (CD) and leprosy, and the carriers with pathogenic mutations of LRRK2 show increased risk to develop particular types of cancer. LRRK2 mutations are rarely found in Alzheimer's disease (AD), but LRRK2 might play a part in tauopathies. The association of LRRK2 with the pathogenesis of apparently unrelated diseases remains enigmatic, but it might be related to the yet unknown diverse functions of LRRK2. Here, we reviewed current knowledge on the link between LRRK2 and several diseases, including PD, AD, CD, leprosy, and cancer, and discussed the possibility of targeting LRRK2 in such diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.